Hepatitis C virus-associated
immune thrombocytopenia (HCV-
ITP) has been assumed to be one of secondary
ITP and associated with antiplatelet
antibodies. This study was to clarify the antibody profile in HCV-
ITP compared with primary
ITP. We enrolled 55 HCV-
ITP, 30 primary
ITP, 11 Helicobacter pylori-
ITP, 21 HCV control, and 16 healthy volunteers. We reviewed their blood cell counts, autoimmune markers, and spleen size. We used
enzyme-linked
immunosorbent assay kit to detect the specific antibody to
glycoproteins IIb/IIIa, Ia/IIa, Ib/IX, IV, and
human leukocyte antigen (HLA) class I. Compared with primary
ITP patients, HCV-
ITP patients had an older age, lower white blood cell (WBC) count and fewer presented with severe
thrombocytopenia. The rate of positive antibody detection was 63.6% for the HCV-
ITP group higher than the rate of 40% for the primary
ITP. In the HCV control, antiplatelet
antibodies were detected in 38.1% patients and no one had more than two types of
antibodies. The antiplatelet
antibodies correlated to severer
thrombocytopenia. An HLA class I antibody was associated with lower WBCs and larger spleen. In conclusion, HCV-
ITP patients had a high rate of positive antiplatelet antibody. The
antibodies were associated with not only lower platelets but also
leukopenia and
splenomegaly.